Bortesun Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Adverse Reactions Drug Interactions MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Concise Prescribing Info

Contents

Bortezomib

Indications/Uses

Adult patients w/ multiple myeloma & mantle cell lymphoma.

Click to view Bortesun detailed prescribing information

Dosage/Direction for Use

Individualized dosage. Recommended starting dose: 1.3 mg/m² administered either as a 3-5 sec IV bolus or SC inj. Multiple myeloma Retreatment: Start at the last tolerated dose. Moderate or severe hepatic impairment Use a lower starting dose.

Click to view Bortesun detailed prescribing information

Contraindications

Hypersensitivity to bortezomib or mannitol. Intrathecal administration.

Click to view Bortesun detailed prescribing information

Special Precautions

Discontinue use if peripheral neuropathy occurs. Pre-existing severe neuropathy; hypotension; dehydration. History of syncope. Concomitant use w/ antihypertensives.

Click to view Bortesun detailed prescribing information

Adverse Reactions

Nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia & anorexia.

Click to view Bortesun detailed prescribing information

Drug Interactions

Concomitant use w/ strong CYP3A4 inhibitors & inducers.

Click to view Bortesun detailed prescribing information

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01XG01 - bortezomib ; Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.

Thai FDA Category

Presentation/Packing

Form

Bortesun powd for inj 3.5 mg

Packing/Price

1's

Bortesun

bortezomib

Manufacturer:

Sun Pharma

Distributor:

DKLL

Marketer:

Ranbaxy